Previous 10 |
New York, NY - ( NewMediaWire ) - November 16, 2021 - PCG Digital -- Following a successful merger, one firm is developing and commercializing therapies for rare skin conditions. Quoin Pharmaceuticals is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devast...
Quoin Pharmaceuticals (NASDAQ:QNRX) have entered into an exclusive license and distribution agreement for QRX003, Quoin’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease. Under the terms of the agreement, Genpharm Services has exclusive rights t...
ASHBURN, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, and Genpharm Services, a regional rare disease and specialty pharmaceutic...
AFT Gains Exclusive Rights to Commercialize QRX003 in Australia and New Zealand ASHBURN, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and ...
Quoin Pharmaceuticals (NASDAQ:QNRX) appointed Gordon Dunn as CFO, effective immediately. The company said Dunn has over 30 years of finance experience. In the past five years he has served as CFO for several private companies, most recently with Qured, a UK-based healthcare provider, fro...
Quoin Pharmaceuticals (NASDAQ:QNRX) has signed an agreement with Queensland University of Technology, Australia (QUT). The agreement is for an exclusive option to a bi-functional protein that has shown promising in-vitro data as a potential treatment for Netherton Syndrome. Under th...
ASHBURN, Va., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has signed an agreement with Queensland Universit...
News, Short Squeeze, Breakout and More Instantly...
Quoin Pharmaceuticals Ltd. Company Name:
QNRX Stock Symbol:
NASDAQ Market:
Quoin Pharmaceuticals Ltd. Website:
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has Been Engaged Plans for the Opening of Additional International Sites at an Advan...
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundat...
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles technology and other approaches will be utilized to optimize the local delivery ...